Loncastuximab Tesirine
CAS: 1879918-31-6
Description:
Loncastuximab tesirine is an antibody-drug conjugate (ADC) used in cancer treatment. It combines an anti-CD19 monoclonal antibody with the cytotoxic agent tesirine. The antibody targets CD19 on B-cell malignancies, delivering tesirine directly to cancer cells. This approach minimizes damage to healthy cells. Loncastuximab tesirine is mainly used to treat B-cell cancers, such as relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Key Features:
- CD19 Targeting: The antibody specifically binds to CD19 on B cells, targeting B-cell cancers directly.
- Cytotoxic Agent (Tesirine): Tesirine inhibits DNA synthesis, leading to cancer cell death.
- Linker Technology: A stable linker connects the antibody to tesirine, releasing the drug inside cancer cells when cleaved.
Applications:
- Cancer Treatment: Targets and destroys CD19-positive cancer cells, primarily for B-cell malignancies like DLBCL.
- Targeted Therapy: Delivers treatment directly to tumor cells, reducing side effects and sparing healthy tissue.
- Monoclonal Antibody Therapy: Offers an option for patients with relapsed or refractory cancers, ensuring a precise, targeted approach.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.